Antibody-mediated delivery of therapeutics for cancer therapy

Expert Opinion on Drug Delivery

Volumn 13, Issue 3, 2016, Pages 401-419

  Parakh, Sagun ^a,b,c   Parslow, Adam C ^a,c   Gan, Hui K ^a,b,c   Scott, Andrew M ^a,b,c,d  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antibody conjugated therapies; immunotoxins; radioimmunotherapy; siRNA

Indexed keywords

ANTIBODY CONJUGATE; CYTOTOXIC AGENT; IMMUNOTOXIN; MONOCLONAL ANTIBODY; NANOPARTICLE; RADIOISOTOPE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

ANTIBODY CONJUGATED THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; HUMAN; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TECHNOLOGY; THERAPY RESISTANCE; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; NEOPLASMS;

EID: 84959551666     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1124854     Document Type: Review

References (171)

1. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins. 2011; 3 (7): 848-883.
2. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013; 64: 15-29.
3. Avivi I, Stroopinsky D, Katz T. Anti-CD20 monoclonal antibodies: beyond B-cells. Blood Rev. 2013; 27 (5): 217-223.
4. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12 (4): 278-287.
5. Teicher B. Antibody-drug conjugate targets. Curr Cancer Drug Targets. 2009; 9 (8): 982-1004.
6. Klute K, Nackos E, Tasaki S., et al. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther. 2014; 7: 2227.
7. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011; 17 (20): 6389-6397.
8. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2007; 41 (1): 98-107.
9. Erickson HK, Park PU, Widdison WC., et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006; 66 (8): 4426-4433.
10. Bander NH. Antibody-drug conjugate target selection: critical factors. Antibody-Drug Conjugates: Springer. 2013;1045: 29-40.
11. Ritchie M, Tchistiakova L, Scott N., et al. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. Taylor & Francis; 2013;5(1):13-21.
12. Hurvitz SA, Dirix L, Kocsis J., et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157-1163.
13. Dieras V, Harbeck N, Albain K., et al. Abstract P3-14-01: A phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Cancer Res. 2010; 70 (24 Supplement): P3-14-01-P3-14-01.
14. Polson AG, Calemine-Fenaux J, Chan P., et al. Antibody-Drug Conjugates for the Treatment of Non-Hodgkins Lymphoma: Target and Linker-Drug Selection. Cancer Res. 2009; 69 (6): 2358-2364.
15. Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84 (5): 548-558.
16. Shen W-C, Ballou B, Ryser HJ., et al. Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells. Cancer Res. 1986; 46 (8): 3912-3916.
17. Johnson DA, Laguzza BC. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. Cancer Res. 1987; 47 (12): 3118-3122.
18. Dillman RO, Johnson DE, Shawler DL., et al. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res. 1988; 48 (21): 6097-6102.
19. Hamblett KJ, Senter PD, Chace DF., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004; 10 (20): 7063-7070.
20. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nature Rev Drug Discovery. 2006; 5 (2): 147-159.
21. Sievers E, Appelbaum F, Spielberger R., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999; 93 (11): 3678-3684.
22. Smith S. Technology evaluation: cantuzumab mertansine, ImmunoGen. Curr Opin Mol Ther. 2004; 6 (6): 666-674.
23. Doronina SO, Toki BE, Torgov MY., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003; 21 (7): 778-784.
24. Sutherland MSK, Walter RB, Jeffrey SC., et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013; 122 (8): 1455-1463.
25. Moldenhauer G, Salnikov AV, Lüttgau S., et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst. 2012; 104 (8): 622-634.
26. Sausville E, Harb W, Ramanathan R., et al. 481P Phase 1 dose-escalation study of the folic acid-tubulysin small molecule drug conjugate EC1456 in patients (pts) with advanced solid tumors. Ann Oncol. 2014; 25 (suppl 4): iv161-iv.
27. Sachdev J, Edelman M, Harb W., et al. S. P1. 08A phase 1 study of 3 different schedules of the folic acid-tubulysin small-molecule drug conjugate EC1456 in pts with advanced solid tumors. Ann Oncol. 2015; 26 (suppl 2): 218-2.
28. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011; 17 (20): 6417-6427.
29. Bross PF, Beitz J, Chen G., et al. Approval summary gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001; 7 (6): 1490-1496.
30. Petersdorf SH, Kopecky KJ, Slovak M., et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013; 121 (24): 4854-4860.
31. Burnett AK, Hills RK, Milligan D., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011; 29 (4): 369-377.
32. Burnett AK, Russell NH, Hills RK., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012; 30 (32): 3924-3931.
33. Castaigne S, Pautas C, Terré C., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379 (9825): 1508-1516.
34. Delaunay J, Recher C, Pigneux A., et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. ASH Annu Meet Abstr. 2011;118:79.
35. Ravandi F, Estey EH, Appelbaum FR., et al. Gemtuzumab ozogamicin: time to resurrect?. J Clin Oncol. 2012; 30 (32): 3921-3923.
36. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013; 121 (24): 4838-4841.
37. De Claro RA, McGinn K, Kwitkowski V., et al. US Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012; 18 (21): 5845-5849.
38. Morschhauser F, Flinn I, Advani RH., et al. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). J Clin Oncol. 2014;32:5s(suppl; abstr 8519).
39. Ott PA, Hamid O, Pavlick AC., et al. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 2014;32(32):3659-3666.
40. Petrylak DP, Smith DC, Appleman LJ., et al. A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32:5s(suppl; abstr 5023).
41. Gordon MS, Gerber DE, Infante JR., et al. A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC). J Clin Oncol. 2014;32:5s(suppl; abstr 2504).
42. Coveler AL, Von Hoff DD, Ko AH., et al. A phase I study of ASG-5ME, a novel antibody-drug conjugate, in pancreatic ductal adenocarcinoma. J Clin Oncol. 2013; 31 (4): abstr 176.
43. Cruz Zambrano C, Almhanna K, Messersmith WA., et al. MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study. J Clin Oncol. 2014;32:5s(suppl; abstr 3546).
44. Infante JR, Sandhu SK, McNeil CM., et al. Abstract CT233: A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma. Cancer Res. 2014; 74 (19 Supplement): CT233-CT.
45. Thompson J, Forero-Torres A, Heath E., et al. The effect of SGN-75, a novel antibody-drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study. J Clin Oncol. 2011;29:15(suppl; abstr 3071).
46. Thompson JA, Motzer R, Molina AM., et al. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). J Clin Oncol. 2015;33(suppl; abstr 2503).
47. Lassman A, Gan H, Fichtel L., et al. A4 Phase 1 Study Evaluating ABT-414 with Temozolomide (TMZ) or Concurrent Radiotherapy (RT) and TMZ in Glioblastoma (GBM)(S43. 006). Neurology. 2015; 84 (14 Supplement): S43-006.
48. Forero-Torres A, Moskowitz C, Advani RH., et al. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol. 2014;32:5s(suppl; abstr 8505).
49. Petersdorf SH, Kopecky KJ, Slovak M., et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013; 121 (24): 4854-4860.
50. Dang NH, Ogura M, Castaigne S., et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol. 2014;32:5s(suppl; abstr 8529).
51. Verma S, Miles D, Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England J Med. 2012; 367 (19): 1783-1791.
52. Berdeja JG, Hernandez-Ilizaliturri F, Chanan-Khan A., et al. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). Blood. 2012;120(21) (suppl; ASH abstr 728).
53. Woll P, Moore K, Bhatia S., et al. Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. J Clin Oncol. 2011;29(suppl; abstr e13582).
54. Stathis A, Maddocks KJ, Flinn I., et al. Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). J Clin Oncol. 2014;32:5s(suppl; abstr 8526).
55. Rosenthal MA., editor. AMG 595: An Antibody Drug Conjugate Directed Against the Mutant Receptor EGFRvIII for the Treatment of Glioblastoma Multiforme Proceedings of the 105th Annual Meeting of the American Association for Cancer Research. San Diego (CA): American Association for Cancer Research (AACR); 2014.
56. Younes A, Kim S, Romaguera J., et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012; 30 (22): 2776-2782.
57. Bendell J, Blumenschein G, Zinner R., et al. Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. Cancer Res. 2013; 73 (8 Supplement): LB-291.
58. Moore K, Martin L, Seward S., et al. Preliminary Single Agent Activity of IMGN853, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Platinum-Resistant Epithelial Ovarian Cancer (EOC) Patients (pts): phase I Trial. J Clin Oncol. 2015;33(suppl; abstr 5518).
59. Boni V, Rixe O, Rasco D., et al. Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870). Mol Cancer Ther. 2013; 12 (11 Supplement): A73-A.
60. Kelly K, Chanan-Khan A, Somlo G., et al. Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Len/Dex-Refractory Patients. Blood. 2014;124(21):4736.
61. Starodub A, Ocean AJ, Messersmith WA., et al. Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): results in patients with metastatic gastrointestinal (GI) cancers. ASCO Annual Meeting Proc. 2015;33(suppl 3; abstr 703).
62. Bonthapally V, Wu E, Macalalad A., et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. Curr Med Res Opin. 2015; 31 (5): 993-1001.
63. Younes A, Gopal AK, Smith SE., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkins lymphoma. J Clin Oncol. 2012; 30 (18): 2183-2189.
64. Moskowitz CH, Nademanee A, Masszi T., et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385 (9980): 1853-1862.
65. Phillips GDL, Li G, Dugger DL., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68 (22): 9280-9290.
66. Barok M, Tanner M, Koninki K., et al. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011; 13 (2): R46.
67. Krop IE, Beeram M, Modi S., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010; 28 (16): 2698-2704.
68. Burris HA, Rugo HS, Vukelja SJ., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011; 29 (4): 398-405.
69. Gan HK, Papadopoulos KP, Fichtel L., et al. Phase I study of ABT-414 mono-or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM). J Clin Oncol. 2015; 33 (suppl): abstr 2016.
70. Hamblett KJ, Kozlosky CJ, Siu S., et al. AMG 595, an anti-EGFRvIII Antibody Drug Conjugate, Induces Potent Anti-Tumor Activity Against EGFRvIII Expressing Glioblastoma. Mol Cancer Ther. 2015;14(7):1614-1624.
71. Oflazoglu E, Kissler KM, Sievers EL., et al. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol. 2008; 142 (1): 69-73.
72. Whittle JR, Lickliter JD, Gan HK., et al First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci. 2015; 22 (12): 1889-1894.
73. Onda M, Kreitman RJ, Vasmatzis G., et al. Reduction of the nonspecific animal toxicity of anti-Tac (Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. The. J Immunol. 1999; 163 (11): 6072-6077.
74. Rajvanshi P, Shulman HM, Sievers EL., et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002; 99 (7): 2310-2314.
75. Schindler J, Sausville E, Messmann R., et al. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkins lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res. 2001; 7 (2): 255-258.
76. Chaudhary VK, Queen G, Junghans RP., et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989; 339 (6223): 394-397.
77. Re GG, Waters C, Poisson L., et al. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. 1996; 56 (11): 2590-2595.
78. Olsen E, Duvic M, Frankel A., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19 (2): 376-388.
79. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs. 2009; 23 (1): 1-13.
80. Telang S, Rasku MA, Clem AL., et al. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer. 2011; 11 (1): 515.
81. Gerena-Lewis M, Crawford J, Bonomi P., et al. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009; 32 (3): 269-273.
82. Barnett B, Ruter J, Brumlik M., et al. A phase II trial of denileukin diftitox to treat refractory advanced-stage ovarian cancer. J Clin Oncol. 2006;24:18s(suppl; abstr 2506).
83. Naumnik W, Chyczewska E. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer. Folia Histochemica Cytobiologica/Polish Academy Sciences, Polish Histochemical Cytochemical Society. 2000; 39: 185-186.
84. Kawashima O, Kamiyoshihara M, Sakata S., et al. The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Ann Surg Oncol. 2000; 7 (3): 239-245.
85. Borthakur G, Rosenblum MG, Talpaz M., et al. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013; 98 (2): 217-221.
86. Schnell R, Borchmann P, Staak JO., et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkins lymphoma. Ann Oncol. 2003; 14 (5): 729-736.
87. Kreitman RJ, Squires DR, Stetler-Stevenson M., et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005; 23 (27): 6719-6729.
88. Kreitman RJ, Stetler-Stevenson M, Margulies I., et al. Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009; 27 (18): 2983-2990.
89. Kreitman RJ, Tallman MS, Robak T., et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012; 30 (15): 1822-1828.
90. Messmann RA, Vitetta ES, Headlee D., et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19 (+), CD22 (+) B cell lymphoma. Clin Cancer Res. 2000; 6 (4): 1302-1313.
91. Sampson JH, Akabani G, Archer GE., et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003; 65 (1): 27-35.
92. Azemar M, Djahansouzi S, Jäger E., et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat. 2003; 82 (3): 155-164.
93. Frankel A, Powell B, Hall P., et al. Phase I trial of a novel diphtheria toxin/GM-CSF fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia (AML). Clin Cancer Res. 2002; 8: 1004-1013.
94. Frankel AE, Fleming DR, Hall PD., et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003; 9 (10): 3555-3561.
95. Dang NH, Hagemeister FB, Pro B., et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkins lymphoma. J Clin Oncol. 2004; 22 (20): 4095-4102.
96. Frankel A, Liu J-S, Rizzieri D., et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008; 49 (3): 543-553.
97. Garland L, Gitlitz B, Ebbinghaus S., et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunotherapy. 2005; 28 (4): 376-381.
98. Parney IF, Kunwar S, McDermott M., et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg. 2005; 102 (2): 267-275.
99. Pai LH, Wittes R, Setser A., et al. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med. 1996; 2 (3): 350-353.
100. Pastan I, Hassan R, FitzGerald DJ., et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6 (7): 559-565.
101. Posey JA, Khazaeli MB, Bookman MA., et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res. 2002; 8 (10): 3092-3099.
102. Kreitman RJ, Wilson WH, White JD., et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000; 18 (8): 1622-1636.
103. Hassan R, Bullock S, Premkumar A., et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin for targeted therapy of mesothelin expressing mesotheliomas, ovarian and pancreatic cancer. Clin Cancer Res. 2007;13(17):5144-5149.
104. Onda M, Willingham M, Wang Q-C., et al. Inhibition of TNF-α produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac (Fv)-PE38, LMB-2. The. J Immunol. 2000; 165 (12): 7150-7156.
105. Jones TD, Crompton LJ, Carr FJ., et al. Deimmunization of monoclonal antibodies. Ther Antibodies: Methods Mol Biol. 2009;525:405-423.
106. Vallera DA, Todhunter DA, Kuroki DW., et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res. 2005; 11 (10): 3879-3888.
107. Flavell DJ, Noss A, Pulford KA., et al. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19,-CD22, and-CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res. 1997; 57 (21): 4824-4829.
108. Herrera L, Farah R, Pellegrini V., et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000; 14 (5): 853-858.
109. Stish B, Oh S, Chen H., et al. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer. 2009; 101 (7): 1114-1123.
110. Fire A, Xu S, Montgomery MK., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391 (6669): 806-811.
111. Elbashir SM, Harborth J, Lendeckel W., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411 (6836): 494-498.
112. Kao SC, Fulham M, Wong K., et al. A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. Am J Respir Crit Care Med. 2015; 191 (12): 1467-1469.
113. Baümer S, Baümer N, Appel N., et al. Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. Clin Cancer Res. 2015; 21 (6): 1383-1394.
114. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med. 2005; 56: 401-423.
115. Guo P. RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol. 2005; 5 (12): 1964.
116. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59 (2): 75-86.
117. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today. 2006; 11 (1): 67-73.
118. De Paula D, Bentley MVL, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. Rna. 2007; 13 (4): 431-456.
119. Barbet J, Bardiès M, Bourgeois M., et al. Radiolabeled antibodies for cancer imaging and therapy. Antibody Engineering: Methods Mol Biol. 2012;907:681-697.
120. Liersch T, Meller J, Kulle B., et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005; 23 (27): 6763-6770.
121. Kaminski MS, Zelenetz AD, Press OW., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkins lymphomas. J Clin Oncol. 2001; 19 (19): 3918-3928.
122. Schoffelen R, Boerman OC, Goldenberg DM., et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013; 109 (4): 934-942.
123. Salaun PY, Campion L, Bournaud C., et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med. 2012; 53 (8): 1185-1192.
124. Sharkey RM, Hajjar G, Yeldell D., et al. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med. 2005; 46 (4): 620-633.
125. Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv. 2011; 8 (1): 26-44.
126. Bander NH, Milowsky MI, Nanus DM., et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005; 23 (21): 4591-4601.
127. Tagawa ST, Milowsky MI, Morris M., et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013; 19 (18): 5182-5191.
128. Vallabhajosula S, Kuji I, Hamacher KA., et al. Pharmacokinetics and biodistribution of 111In-and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?. J Nucl Med. 2005; 46 (4): 634-641.
129. Picozzi VJ, Ramanathan RK, Lowery MA., et al. Feasibility and results of a randomized phase Ib study of fractionated 90 {Upsilon}-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. J Clin Oncol. 2014;32:15(suppl; abstr: 4026).
130. Epenetos A, Hird V, Lambert H., et al. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecological Cancer. 2000; 10 (51): 44-46.
131. Richman CM, Denardo SJ, ODonnell RT., et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005; 11 (16): 5920-5927.
132. Stillebroer AB, Boerman OC, Desar IM., et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013; 64 (3): 478-485.
133. Divgi CR, Bander NH, Scott AM., et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998; 4 (11): 2729-2739.
134. Alvarez RD, Huh WK, Khazaeli M., et al. A phase I study of combined modality 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002; 8 (9): 2806-2811.
135. Chen S, Yu L, Jiang C., et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005; 23 (7): 1538-1547.
136. Kramer K, Humm JL, Souweidane MM., et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007; 25 (34): 5465-5470.
137. Meredith R, Torgue J, Shen S., et al. Dose escalation and dosimetry of first-in-human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. 2014; 55 (10): 1636-1642.
138. Meredith RF, Torgue J, Azure MT., et al. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 2014; 29 (1): 12-17.
139. Wiseman GA, Gordon LI, Multani PS., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002; 99 (12): 4336-4342.
140. Witzig TE, Flinn IW, Gordon LI., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkins lymphoma. J Clin Oncol. 2002; 20 (15): 3262-3269.
141. Witzig TE, Molina A, Gordon LI., et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007; 109 (9): 1804-1810.
142. Shimoni A, Avivi I, Rowe JM., et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012; 118 (19): 4706-4714.
143. Morschhauser F, Radford J, Van Hoof A., et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. J Clin Oncol. 2013; 31 (16): 1977-1983.
144. Morschhauser F, Radford J, Van Hoof A., et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008; 26 (32): 5156-5164.
145. Hainsworth JD, Spigel DR, Markus TM., et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clinical Lymphoma Myeloma. 2009; 9 (3): 223-228.
146. Jacobs SA, Swerdlow SH, Kant J., et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008; 14 (21): 7088-7094.
147. Provencio M, Cruz Mora MÁ, Gómez-Codina J., et al. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate-and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. Leuk Lymphoma. 2014; 55 (1): 51-55.
148. Vose JM, Wahl RL, Saleh M., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkins lymphomas. J Clin Oncol. 2000; 18 (6): 1316-1323.
149. Fisher RI, Kaminski MS, Wahl RL., et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkins lymphomas. J Clin Oncol. 2005; 23 (30): 7565-7573.
150. Link BK, Martin P, Kaminski MS., et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and Iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol. 2010; 28 (18): 3035-3041.
151. Bennett JM, Kaminski MS, Leonard JP., et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005; 105 (12): 4576-4582.
152. Vose JM, Carter S, Burns LJ., et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013; 31 (13): 1662-1668.
153. Rose AC, Shenoy PJ, Garrett G., et al. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2012; 12 (6): 393-399.
154. GSK to discontinue manufacture and sale of the BEXXAR® Therapeutic Regimen (tositumomab and iodine I 131 tositumomab) 2013. [ cited 2013 Aug 07[. Available from: http://www.gsk.ca/english/html/media-centre/2013-08-07.html.
155. Kraeber-Bodéré F, Bodet-Milin C, Rousseau C., et al. Radioimmunoconjugates for the Treatment of Cancer. Semin Oncol. 2014;41(5):613-622.
156. Verheijen RH, Massuger LF, Benigno BB., et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006; 24 (4): 571-578.
157. Sakamoto J, Kojima H, Kato J., et al. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol. 2000; S1: SS27-32.
158. Garinchesa P, Sakamoto J, Welt S., et al. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol. 1996; 9 (3): 465-471.
159. Daghighian F, Barendswaard E, Welt S., et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med. 1996; 37 (6): 1052-1057.
160. King DJ, Antoniw P, Owens RJ., et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995; 72 (6): 1364-1372.
161. Chong G, Lee FT, Hopkins W., et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005; 11 (13): 4818-4826.
162. Herbertson RA, Tebbutt NC, Lee FT., et al. Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. J Nucl Med. 2014; 55 (4): 534-539.
163. Ng B, Kramer E, Liebes L., et al. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts. Cancer Res. 2001; 61 (7): 2996-3001.
164. Behr TM, Wulst E, Radetzky S., et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 1997; 57 (23): 5309-5319.
165. Stein R, Juweid M, Zhang C-H., et al. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer. Clin Cancer Res. 1999; 5 (10): 3199s-206s.
166. Lippert TH, H-J R, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittel-Forschung. 2007; 58 (6): 261-264.
167. Chen R, Hou J, Newman E., et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015; 14 (6): 1376-1384.
168. Szakács G, Paterson JK, Ludwig JA., et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discovery. 2006; 5 (3): 219-234.
169. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53 (1): 615-627.
170. Sammet B, Steinkühler C, Sewald N. Antibody-drug conjugates in tumor therapy. Pharmaceutical Patent Analyst. 2012; 1 (1): 65-73.
171. Loo T, Clarke D. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. The. J Membr Biol. 2005; 206 (3): 173-185.